Skip to main content
PLOS One logoLink to PLOS One
. 2023 Mar 10;18(3):e0282345. doi: 10.1371/journal.pone.0282345

Somatic burden in Russia during the COVID-19 pandemic

Alena Zolotareva 1,*, Anna Khegay 1, Elena Voevodina 1, Igor Kritsky 2, Roman Ibragimov 2, Nina Nizovskih 3, Vsevolod Konstantinov 4, Arina Malenova 5, Irina Belasheva 6, Natalia Khodyreva 7, Vladimir Preobrazhensky 1, Kristina Azanova 1, Lilia Sarapultseva 8, Almira Galimova 9, Inna Atamanova 10, Anastasia Kulik 11, Yulia Neyaskina 11, Maksim Lapshin 12, Marina Mamonova 13, Ruslan Kadyrov 14, Ekaterina Volkova 14, Viktoria Drachkova 7, Andrey Seryy 15, Natalia Kosheleva 1, Evgeny Osin 1,16
Editor: Ahmet Murt17
PMCID: PMC10004591  PMID: 36897839

Abstract

Somatic burden has become one of the most common psychological reactions to the COVID-19 pandemic worldwide. This study examined the prevalence of somatic burden, latent profiles, and associated factors of somatic symptoms during the pandemic in a large sample of Russians. We used cross-sectional data from 10,205 Russians collected during October-December, 2021. Prevalence of somatic burden was assessed with the Somatic Symptom Scale-8. Latent profiles of somatic burden were identified using latent profile analysis. Multinomial logistic regression was used to examine demographic, socioeconomic, and psychological associated factors of somatic burden. Over one-third (37%) of the Russians reported being somatised. We selected the three-latent profile solution with high somatic burden profile (16%), medium somatic burden profile (37%), and low somatic burden profile (47%). The associated factors of greater somatic burden were female gender, lower education, history of COVID-19 disease, refusing vaccination against SARS-CoV-2 infection, poorer self-rated health, greater fear of COVID-19 pandemic, and living in regions with higher excess mortality. Overall, this study contributes to knowledge about the prevalence, latent profiles, and associated factors of somatic burden during the COVID-19 pandemic. It can be useful to researchers in psychosomatic medicine and practitioners in the health care system.

Introduction

The COVID-19 pandemic, with over 526 million confirmed cases and over six million deaths (World Health Organization data as of May 29, 2022), has caused serious damage to the mental and physical health of the world’s population. Numerous studies suggested that 30.7% of persons experience somatic symptoms, which exceeds the general prevalence of some other mental health issues, for instance 16.4% for suicide ideation, 6.4% for obsessive-compulsive symptoms, 25.7% for panic disorder, 2.4% for phobia anxiety, 22.8% for adjustment disorder, and 1.2% for suicide attempts [1].

Many mental health issues can be expressed psychosomatically with the experience of somatic symptoms replacing or combining with the symptoms of psychological distress [2]. Somatic symptoms during the first waves of the COVID-19 pandemic were reported by 23.8% of Spaniards [3], 29% of Germans [4], 31.1% of Iranians [5], 45.9% of Chinese [6], and 62.6% of Brazilians [7]. Physical complaints were most frequently manifested in vulnerable groups, such as health-care workers [8], cancer patients [9], chronic disease patients [10], and patients awaiting transplantation [11]. Sometimes somatic symptoms were observed during the recovery period after the COVID-19 disease. Three months after hospitalization for СOVID-19, 23.5% of patients reported body aches, 20.3% fatigue, 19% shortness of breath, and 13.1% headaches [12]. Interestingly, persistent physical complaints expressed 10 to 12 months after the first wave of COVID-19 pandemic were more strongly associated with the person’s belief in having experienced COVID-19 disease than with having had a laboratory-confirmed SARS-CoV-2 infection [13].

Before the pandemic, some researchers studied somatic symptoms using latent class analysis (LCA) or latent profile analysis (LPA). These analyses are variants of a person-centered statistical approach aiming to find out subtypes of related cases in empirical data and establish whether there are subgroups of individuals with similar symptom profiles [14]. Generally, researchers derived between three and eight latent classes of somatic symptoms. In one study, a three-class solution revealed subgroups with low, moderate, and high psychosomatic burden differing mostly in the extent, rather than in the qualitative combinations of somatic symptoms [15]. In another study, a five-class solution detected subgroups without any health problems, with multiple somatic symptoms, and with specific symptom patterns reflecting abnormal tiredness, gastrointestinal problems, and pain-related symptoms [16]. In a third study, an eight-class solution identified subgroups without somatic symptoms, with a high burden of all somatic symptoms, three intermediate classes with specific symptoms of muscle and joint pain, gastrointestinal symptoms, general symptoms, and three intermediate classes characterized by combinations of specific somatic symptoms [17].

We aimed to replicate and extend these previous findings by examining the prevalence of somatic burden, investigating the latent profiles and predictors of somatic symptoms during the COVID-19 pandemic in a large sample of Russians. Specifically, we expected that somatic burden during the COVID-19 pandemic should be associated to some extent with known pre-pandemic risk factors and demographics, such as female gender, older age, not being in a partnership, lower education background [1820], but might be more dependent on health- and pandemic-related risk factors, such as poorer self-rated health, history of COVID-19 disease, refusing vaccination against SARS-CoV-2 infection, greater fear of COVID-19 pandemic, living in regions with higher excess mortality, and preventive behavior during the COVID-19 pandemic.

Methods

Participants

The online quantitative survey “Somatic Burden in Russia” recruited volunteers who were at least 18 years old and resident in Russia between October and December, 2021. Participants who did not meet these criteria were excluded from the survey. The survey included a participant information sheet explaining the study aims and objectives, an informed consent page, a sociodemographic form, and questionnaires measuring self-rated health, somatic burden, fear of COVID-19, and preventive behavior. The survey invitation was advertised using social media popular in Russia, including Instagram, Facebook, VKontakte, Telegram, and WhatsApp groups.

Measures

The respondents completed a sociodemographic form followed by a one-item self-rated health measure aimed to evaluate the general health status as “poor”, “fair”, “good”, “very good”, or “excellent” [21]. Next, the survey included the following questionnaires:

Somatic Symptoms Scale (SSS-8) [22]. The SSS-8 assesses eight somatic complaints during the past seven days (stomach or bowel problems; back pain; pain in arms, legs, or joints; headaches; chest pain or shortness of breath; dizziness; feeling tired or having low energy; trouble sleeping). Symptoms are scored on a five-point response option from 0 (“not bothered at all”) to 4 (“bothered very much”). The cut-off score for somatic burden is ≥ 12, with the severity of somatic symptoms characterized as minimal (0–3 points), low (4–7 points), medium (8–11 points), high (12–15 points), or very high degree of somatic symptoms (16–32 points). In the present sample, the translated Russian version of the SSS-8 showed good reliability (Cronbach’s α = 0.831).

Fear of COVID-19 Scale (FCV-19S) [23]. The FCV-19S is a seven-item scale measuring psychological and physiological responses to fear associated with the SARS-CoV-2 infection and COVID-19 pandemic. Responses can range from 1 (“strongly disagree”) to 5 (“strongly agree”). We used the Russian version of the FCV-19S [24]. In the present sample, the FCV-19S showed good reliability (Cronbach’s α = 0.831).

СOVID-19 Preventive Behavior Index (CPBI) [25]. The CPBI is a ten-item scale evaluating preventive behaviors aimed at reducing exposure to the SARS-CoV-2 infection and COVID-19 pandemic (wearing a facemask, regular hand hygiene, maintaining social distance, avoiding any non-essential local and international travel, etc.). Responses are ranged from 1 (“strongly disagree”) to 5 (“strongly agree”). In the present sample, the translated Russian version of the CPBI showed good reliability (Cronbach’s α = 0.861).

We also used statistics on excess mortality in Russia’s regions based on the average values for October, November, and December 2021 [26].

Data analysis

The data were analyzed using RStudio and visualized using Python and RStudio. Means and standard deviations for continuous variables and frequencies and percentages for categorical variables were calculated to summarize participant characteristics. Percentages and the adjusted odds ratio with 95% CI were calculated to examine the prevalence of somatic burden. Latent profile analysis (LPA) was performed to identify the optimal number of participant latent profiles based on eight somatic symptoms measured by the SSS-8. The optimal model was selected based on theoretical support and a combination of statistical indices, including the Akaike information criterion (AIC) [27], Bayesian information criterion (BIC) [28], and bootstrap likelihood ratio test (BLRT) [29]. For AIC and BIC, lower values show better model fit. The information criteria and BLRT were used to decide whether a model with k profiles was superior to the another less parsimonious model with k-1 profile. Entropy values were also identified. These values can range from 0 to 1, with higher values showing greater accuracy of classification and values above 0.80 signifying classification with minimal uncertainty [30]. After selecting the final latent profile solution, we examined multinomial regression models to predict compliance patterns as associated factors of somatic burden.

Ethical considerations

This study was approved by the Ethics Committee of the School of Psychology, HSE University (minutes of the meeting of October 25, 2021). The participants gave written informed consent.

Results

Descriptive statistics

Participant and descriptive characteristics are presented in Table 1. The study sample comprised 10,205 persons from 33 regions of Russia (see Fig 1).

Table 1. Participant and descriptive characteristics.

Characteristic Mean (SD) or n (%)
Gender, female participants, n (%) 7,766 (77.5)
Age (in years), mean (SD) 36.10 (14.11)
Educational background, university, n (%) 7,443 (73.5)
Partnership status, being in a partnership, n (%) 6,063 (59.9)
History of COVID-19 disease n (%) 6,102 (60.1)
Vaccination against SARS-CoV-2, n (%) 5,597 (55.2)
Self-rated health, mean (SD) 3.78 (0.81)
Fear of COVID-19, mean (SD) 15.97 (5.31)
Preventive behavior during the COVID-19, mean (SD) 33.52 (8.44)

Fig 1. Somatic burden prevalence by Russia’s regions.

Fig 1

Prevalence of somatic burden

Over one-third (37%) of the participants reported being somatised. A total of 16.8% of the respondents were free from somatic burden, 23.9% had low somatic burden, 22.2% had medium somatic burden, 17.4% had high somatic burden, and 19.7% had very high somatic burden. Fig 1 shows prevalence of somatic burden by Russia’s regions, illustrating important variations ranging from 21.6% in the Primorye Territory to 49.7% in the Ulyanovsk Region.

Latent profiles of somatic burden

Table 2 presents fit indices of the models with an increasing number of somatic burden profiles. The models with one latent profile and two latent profiles had the greatest AIC and BIC, suggesting that these models fit the data the worst. The model with three latent profiles had lower AIC and BIC values, and further separation of four or five latent profiles did not improve these fit statistics essentially. Entropy values close to 1 are preferred, evidencing better profile separation [30]. The models showed a decrease in values from one to five profiles. Although the goodness-of-fit indices were not in full agreement to support a single model, we opted for the three-profile solution based on previous theoretical, empirical, and practical considerations on the separation of low, medium, and high somatisers in clinical and general population [15, 31, 32].

Table 2. Summary of fit statistics for latent profile models based on eight somatic symptoms.

Model AIC BIC Entropy BLRT
1 latent profile 232,661.81 232,777.57 1.00
2 latent profiles 213,661.72 213,842.59 0.84 0.01
3 latent profiles 209,118.91 209,364.89 0.80 0.01
4 latent profiles 207,598.86 207,909.95 0.78 0.01
5 latent profiles 207,616.26 207,992.47 0.68 0.01

The response patterns characterising the three latent profiles of somatic burden are shown in Fig 2. The first latent profile includes 16% of the participants with generally high severity of stomach or bowel problems, back pain, pain in arms, legs, or joints, headaches, feeling tired or having low energy, and trouble sleeping combined with even more pronounced dizziness and extremely high levels of chest pain or shortness of breath. This latent profile can be described as a “high somatic burden profile”. The second latent profile contains 37% of the participants showing moderate complaints of stomach or bowel problems, back pain, pain in arms, legs, or joints, headaches, feeling tired or having low energy, and trouble sleeping with somewhat lower mentions of dizziness and chest pain or shortness of breath. This latent profile can be referred to as the “medium somatic burden profile”. The las and most numerous latent profile contains 47% of the participants and can be labelled as “low somatic burden profile”, as participants in this profile reported low severity of all somatic symptoms. This suggests that for almost half of the survey sample, somatic burden might not be a typical way of responding to the COVID-19 pandemic. In Fig 2, the y-axis shows the z-scores reflecting the levels of somatic burden, while the x-axis represents eight specific somatic symptoms used for the LPA. The three lines illustrate patterns for the three somatic burden latent profiles.

Fig 2. The three somatic burden latent profiles characterized by their patterns of the eight somatic symptoms.

Fig 2

Symptoms: 1 = stomach or bowel problems; 2 = back pain; 3 = pain in arms, legs, or joints; 4 = headaches; 5 = chest pain or shortness of breath; 6 = dizziness; 7 = feeling tired or having low energy; 8 = trouble sleeping.

Associated factors of somatic burden

The associations of somatic burden with other variables are displayed in Fig 3. Compared with high somatisers, there was clear evidence that medium somatisers have higher education (OR = 1.21, 95% CI 1.04 to 1.40), more rarely reported history of COVID-19 disease (OR = 0.58, 95 CI 0.50 to 0.67), greater self-rated health (OR = 2.68, 95% CI 2.43 to 2.96), lower fear of the pandemic (OR = 0.96, 95% CI = 0.95 to 0.97), and live in regions with lower excess mortality (OR = 1.00, 95% CI 1.00 to 1.00). Similar, but more extensive associations were found with a larger gap in somatic burden between participants. Compared with high somatisers, low somatisers were more often male respondents (OR = 0.47, 95% CI 0.39 to 0.58), more likely to have higher education (OR = 1.29, 95% CI 1.08 to 1.54), less likely to report history of COVID-19 disease (OR = 0.46, 95% CI = 0.39 to 0.55), more frequently reported vaccination against SARS-CoV-2 infection (OR = 0.71, 95% CI 0.61 to 0.83), greater self-rated health (OR = 8.07, 95% CI 7.13 to 9.18), lower fear of the pandemic (OR = 0.93, 95% 0.91 to 0.95), and live in regions with lower excess mortality (OR = 1.00, 95% CI 1.00 to 1.00). Thus, female gender, lower education, history of COVID-19 disease, refusing vaccination against SARS-CoV-2 infection, poorer self-rated health, greater fear of COVID-19 pandemic, and living in regions with higher excess mortality were associated with greater somatic burden.

Fig 3. Results of multinomial regression model of somatic burden latent profile on participant characteristics.

Fig 3

Profiles: 1 = high somatic burden profile; 2 = medium somatic burden profile; 3 = low somatic burden profile.

Discussion

To our knowledge, this study is the largest to specifically focus on examining the prevalence of somatic burden in Russia. We found that 37% of the Russians reported being somatised, with an important variation of prevalence across regions ranging from 21.6% in the Primorye Territory to 49.7% in the Ulyanovsk Region. These data show that the somatic burden in Russia during the COVID-19 pandemic is lighter than in China [6] and Brazil [7], but heavier than in Spain [3], Germany [4], and Iran [5]. A World Health Organization study evidenced that some somatic symptoms are the most common complaints in different countries, but there are culture- or geographic area-specific symptoms, such as “numbness” and “feelings of heat” in Africa, “burning hands and feet” in India, and “fatigue” in Western countries [20]. The possible differences in symptom prevalence between Russia’s regions can be related to a large number of factors, such as geographic features, socioeconomic status, rates of morbidity and mortality from SARS-CoV-2 infection, residents’ attitudes toward the COVID-19 pandemic, and trust in local government authorities.

We found three latent profiles describing Russians with low, medium, and high somatic burden during the COVID-19 pandemic, which corresponds to a previously discovered classification of participants with somatic complaints [15]. Surprisingly, the medium and high somatic burden profiles form a diamond-shaped pattern with dizziness and chest pain or shortness of breath increased in the highly somatising group and decreased in the moderately somatising group. There could be two possible interpretations of these findings. Dizziness and chest pain are considered as physiological symptoms of panic attacks, and panic attacks are a common phenomenon among persons with somatoform disorders [33]. This means that persons with high somatic burden can react panically to physical symptoms resembling COVID-19 disease. Dizziness and chest pain are also considered as long-term effects of SARS-CoV-2 infection [34]. Because persistent somatic symptoms are seen in patients suffering from post-acute long COVID [35], and most respondents noted a history of the disease, some of them may have experienced post-acute COVID-19 syndrome with dizziness, chest pain, and shortness of breath.

The associated factors of greater somatic burden were female gender, lower education, history of COVID-19 disease, refusing vaccination against SARS-CoV-2 infection, poorer self-rated health, greater fear of COVID-19 pandemic, and living in regions with higher excess mortality. Previous research showed the associations of somatic burden with female gender [36] and fear of the pandemic [37], but not with lower education [38] and refusing vaccination against SARS-CoV-2 infection [39]. The fact that vaccination against SARS-CoV-2 infection, but not lower education and preventive behavior during the pandemic was associated with lower somatic symptoms evidenced the trust in medicine and good awareness about the pandemic among Russians. Importantly, the strongest associated factor was poor self-rated health, which may suggest that a person’s doubts about his or her health play a key role in the formation and aggravation of somatic symptoms during the COVID-19 pandemic. The pre-pandemic study found that non-specific health complaints and a poor self-rated health in pre-adolescents were associated with greater past and future use of general practitioners [31].

Despite strengths, this study has a number of limitations. The online survey setting limits our ability to investigate the possible causes of reported somatic symptoms, which could be associated with mental or physical disorders. This study also relies on self-report data, making it impossible to accurately determine certain participant characteristics, such as their demographic features, history of COVID-19 disease, and experience of vaccination against SARS-CoV-2 infection. We suppose that many participants may have experienced the COVID-19 disease asymptomatically or, conversely, may have interpreted some somatic complaints as symptoms of the COVID-19 disease. Similarly, unvaccinated persons may misrepresent their vaccination status because of stigmatisation [40]. Future studies could rely on objective data (medical records, laboratory tests, physician evaluations, etc.). This study covered only eight somatic symptoms for which we identified latent somatic burden profiles. Previous studies included 9 [16], 12 [15], and 31 somatic symptoms [17], resulting in a greater number of somatic burden latent profiles.

Conclusions

This study contributes to our knowledge of the prevalence, latent profiles, and associated factors of somatic burden during the COVID-19 pandemic and may extend the previous findings and contribute to improving the existing practices in psychosomatic medicine. This is also the first large-scale study of somatic symptoms among Russians, and we hope that our findings will open up prospects for new investigations of mental and physical health issues in Russia.

Acknowledgments

We are grateful to the participants, as well as thankful to the editors and anonymous reviewers.

Data Availability

The study data are available at https://osf.io/9hw52/.

Funding Statement

The study was supported by HSE University Basic Research Program.

References

  • 1.Nochaiwong S, Ruengorn C, Thavorn K, Hutton B, Awiphan R, Phosuya C, et al. Global prevalence of mental health issues among the general population during the coronavirus disease-2019 pandemic: A systematic review and meta-analysis. Sci. Rep. 2021; 11:10173. doi: 10.1038/s41598-021-89700-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lipowski ZJ. Somatization: The experience and communication of psychological distress as somatic symptoms. Psychother. Psychosom. 1987; 47(3–4):160–167. doi: 10.1159/000288013 [DOI] [PubMed] [Google Scholar]
  • 3.Pérez S, Masegoso A, Hernández-Espeso N. Levels and variables associated with psychological distress during confinement due to the coronavirus pandemic in a community sample of Spanish adults. Clin. Psychol. Psychother. 2021; 28(3):606–614. doi: 10.1002/cpp.2523 [DOI] [PubMed] [Google Scholar]
  • 4.Biermann M, Vonderlin R, Mier D, Witthöft M, Bailer J. Predictors of psychological distress and coronavirus fears in the first recovery phase of the coronavirus disease 2019 pandemic in Germany. Front. Psychol. 2021; 12:e678860. doi: 10.3389/fpsyg.2021.678860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mohammadi MR, Zarafshan H, Bashi SK, Mohammadi F, Khaleghi A. The role of public trust and media in the psychological and behavioral responses to the COVID-19 pandemic. Iran. J. Psychiatry. 2020; 15(3):189–204. doi: 10.18502/ijps.v15i3.3811 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ran L, Wang W, Ai M, Kong Y, Chen J, Kuang L. Psychological resilience, depression, anxiety, and somatization symptoms in response to COVID-19: A study of the general population in China at the peak of its epidemic. Soc. Sci. Med. 2020; 262:113261. doi: 10.1016/j.socscimed.2020.113261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Goularte JF, Serafim SD, Colombo R, Hogg B, Caldieraro MA, Rosa AR. COVID-19 and mental health in Brazil: Psychiatric symptoms in the general population. J. Psychiatr. Res. 2021; 132:32–37. doi: 10.1016/j.jpsychires.2020.09.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Conti C, Fontanesi L, Lanzara R, Rosa I, Porcelli P. Fragile heroes. The psychological impact of the COVID-19 pandemic on health-care workers in Italy. PLoS One. 2020; 15(11):e0242538. doi: 10.1371/journal.pone.0242538 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mishra S, Gupta R, Bhatnagar S, Garg R., Bharati SJ, Kumar V, et al. The COVID-19 pandemic: A new epoch and fresh challenges for cancer patients and caregivers–a descriptive cross-sectional study. Support. Care Cancer. 2022; 30(3):1547–1555. doi: 10.1007/s00520-021-06564-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Louvardi M, Pelekasis P, Chrousos GP, Darviri C. Mental health in chronic disease patients during the COVID-19 quarantine in Greece. Palliat. Support. Care. 2020; 18(4):394–399. doi: 10.1017/S1478951520000528 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wagner-Skacel J, Dalkner N, Bengesser S, Ratzenhofer M, Fink N, Kahn J, et al. COVID-19 pandemic stress-induced somatization in transplant waiting list patients. Front. Psychiatry. 2021; 12:e671383. doi: 10.3389/fpsyt.2021.671383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liyanage-Don NA, Cornelius T, Sanchez JE, Trainor A, Moise N, Wainberg M, et al. Psychological distress, persistent physical symptoms, and perceived recovery after COVID-19 illness. J. Gen. Intern. Med. 2021; 36:2525–2527. doi: 10.1007/s11606-021-06855-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern. Med. 2022; 182(1): 19–25. doi: 10.1001/jamainternmed.2021.6454 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Colins LM, Lanza ST. Latent class and latent transition analysis: With applications in the social, behavioral, and health sciences. Hoboken, NJ: Wiley; 2010. [Google Scholar]
  • 15.Burri A, Hilpert P, McNair P, Williams FM. Exploring symptoms of somatization in chronic widespread pain: Latent class analysis and the role of personality. J. Pain Res. 2017; 10:1733–1740. doi: 10.2147/JPR.S139700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kato K, Sullivan PF, Pedersen NL. Latent class analysis of functional somatic symptoms in a population-based sample of twins. J. Psychosom. Res. 2010; 68(5):447–453. doi: 10.1016/j.jpsychores.2010.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Eliasen M, Schröder A, Fink P, Kreiner S, Dantoft TM, Poulsen CH, et al. A step towards a new delimitation of functional somatic syndromes: A latent class analysis of symptoms in a population-based cohort study. J. Psychosom. Res. 2018; 108:102–117. doi: 10.1016/j.jpsychores.2018.03.002 [DOI] [PubMed] [Google Scholar]
  • 18.Beutel ME, Wiltink J, Ghaemi Kerahrodi J., Tibubos AN, Brähler E, Schulz A, et al. Somatic symptom load in men and women from middle to high age in the Gutenberg Health Study—association with psychosocial and somatic factors. Sci. Rep. 2019; 9:4610 doi: 10.1038/s41598-019-40709-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Creed FH, Davies I, Jackson J, Littlewood A, Chew-Graham C, Tomenson B, et al. The epidemiology of multiple somatic symptoms. J. Psychosom. Res. 2012;72:311–317. doi: 10.1016/j.jpsychores.2012.01.009 [DOI] [PubMed] [Google Scholar]
  • 20.Gureje O, Simon GE, Ustun TB, Goldberg DP. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am. J. Psychiatry. 1997; 154(7):989–995. doi: 10.1176/ajp.154.7.989 [DOI] [PubMed] [Google Scholar]
  • 21.Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J. Clin. Epidemiol. 1998; 51(11):903–912. doi: 10.1016/s0895-4356(98)00081-x [DOI] [PubMed] [Google Scholar]
  • 22.Gierk B, Kohlmann S, Kroenke K, Spangenberg L, Zenger M, Brähler E, et al. The somatic symptom scale-8 (SSS-8): A brief measure of somatic symptom burden. JAMA Intern. Med. 2014; 174(3):399–407. doi: 10.1001/jamainternmed.2013.12179 [DOI] [PubMed] [Google Scholar]
  • 23.Ahorsu DK, Lin C-Y, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID-19 scale: Development and initial validation. Int. J. Ment. Health Addict. 2022; 20(3):1537–1545. 10.1007/s11469-020-00270-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Reznik A, Gritsenko V, Konstantinov V, Khamenka N, Isralowitz R. COVID-19 fear in Eastern Europe: Validation of the Fear of COVID-19 Scale. Int. J. Ment. Health Addict. 2021; 19(5):1903–1908. doi: 10.1007/s11469-020-00283-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Breakwell GM, Fino E, Jaspal R. The COVID-19 Preventive Behaviors Index: Development and validation in two samples from the United Kingdom. Eval. Health Prof. 2021; 44(1):77–86. doi: 10.1177/0163278720983416 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kobak D. Excess mortality reveals Covid’s true toll in Russia. Signif. 2021; 18(1):16–19. doi: 10.1111/1740-9713.01486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Akaike H. Factor analysis and AIC. Psychometrika. 1987; 52:317–332. 10.1007/BF02294359 [DOI] [Google Scholar]
  • 28.Schwarz G. Estimating the dimension of a model. Ann. Stat. 1978; 6(2): 461–464. 10.1214/aos/1176344136 [DOI] [Google Scholar]
  • 29.McLachlan G, Peel D. Finite mixture models. New York: John Wiley & Sons, Inc. M.; 2000. [Google Scholar]
  • 30.Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. J. Classif. 1996; 13:195–212. 10.1007/BF01246098 [DOI] [Google Scholar]
  • 31.Rytter D, Rask CU, Vestergaard CH, Nybo Andersen A-M, Bech BH. Non-specific Health complaints and self-rated health in pre-adolescents; impact on primary health care use. Sci. Rep. 2020; 10:3292. doi: 10.1038/s41598-020-60125-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tingstedt O, Lindblad F, Koposov R, Blatný M, Hrdlička M, Stickley A, et al. Somatic symptoms and internalizing problems in urban youth: A cross-cultural comparison of Czech and Russian adolescents. Eur. J. Public Health. 2018; 28(3):480–484. doi: 10.1093/eurpub/cky001 [DOI] [PubMed] [Google Scholar]
  • 33.Ma M, Shi Z, Wu H, Ma X. Clinical implications of panic attack in Chinese patients with somatoform disorders. J. Psychosom. Res. 2021; 146:110509. doi: 10.1016/j.jpsychores.2021.110509 [DOI] [PubMed] [Google Scholar]
  • 34.Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P., Cuapio A., et al. (2021). More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021; 11:16144. 10.1038/s41598-021-95565-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nguyen N, Hoang V, Dao T, Dudouet P, Eldin C, Gautret P. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: A systematic review. Eur. J. Clin. Microbiol. Infect. Dis. 2022; 41:515–545. doi: 10.1007/s10096-022-04417-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Abreu L, Koebach A, Díaz O, Carleial S, Hoeffler A, Stojetz W, et al. Life with Corona: Increased gender differences in aggression and depression symptoms due to the COVID-19 pandemic burden in Germany. Front. Psychol. 2021; 12:689396. doi: 10.3389/fpsyg.2021.689396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Shevlin M, Nolan E, Owczarek M, McBride O, Murphy J, Miller JG, et al. COVID-19-related anxiety predicts somatic symptoms in the UK population. Br. J. Health Psychol. 2020; 25(4):875–882. doi: 10.1111/bjhp.12430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Petersen MW, Dantoft TM, Jensen JS, Pedersen HF, Frostholm L, Benros ME, et al. The impact of the Covid-19 pandemic on mental and physical health in Denmark–a longitudinal population-based study before and during the first wave. BMC Public Health. 2021; 21:1418. doi: 10.1186/s12889-021-11472-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Simione L, Vagni M, Gnagnarella C, Bersani G, Pajardi D. Mistrust and beliefs in conspiracy theories differently mediate the effects of psychological factors on propensity for COVID-19 vaccine. Front. Psychol. 2021; 12:683684. doi: 10.3389/fpsyg.2021.683684 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kampf G. COVID-19: Stigmatising the unvaccinated is not justifies. Lancet. 2021; 398(10314):1871. 10.1016/S0140-6736(21)02243-1 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Ahmet Murt

17 Oct 2022

PONE-D-22-18719Somatic burden in Russia during the COVID-19 pandemicPLOS ONE

Dear Dr. Zolotareva,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ahmet Murt

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I think it is a good article evaluating the somatic burden.

Minor Points

- In Table 1, I think that it is not necessary to give all the cities where the participants in the study live. The table seems too long.

- Table 1 presents data on the results of the Fear of COVID-19 Scale and the СOVID-19 Preventive Behavior Index. Therefore, it would be more appropriate to give Table 1 after the explanations of these scales.

-Typos should be corrected.

Reviewer #2: In this article, authors have researched the somatic burden of Russian population during COVID-19 pandemic. The scales and number of participants are acceptable.

However, the paper needs some modifications before it can proceed to the publication stage:

1- Why didn't the authors exclude any patients with any previous psychological or psychiatric illnesses?

2- Do we have any information about previous health problems of the participants? There might appear a difference between those who have and those who don't have.

3- In somatic symptom scale, authors state that there are 4 levels of symptoms: minimal, low, medium, high, very high. However in latent profiles there are only low, medium and high levels. Can the authors explain why they reduced the number of profile classes?( (It's stated that goodness for fit model does not indicate the superiority of any other)

4- Although females are given and discussed as higher somatizers, it is said in associated factors of somatic burden that 'low somatisers were more often females'. This should be corrected.

5- Authors should explain their selection criteria for the multinomial regression model.

6- May authors also discuss the reasons for differences between different cities or regions? Do any of these regions have any specific characteristics?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Mar 10;18(3):e0282345. doi: 10.1371/journal.pone.0282345.r002

Author response to Decision Letter 0


4 Nov 2022

Dear Reviewers,

Thank you for your help in improving our manuscript. We have made the modifications following your suggestions:

In Table 1, I think that it is not necessary to give all the cities where the participants in the study live. The table seems too long.

Thank you, for brevity we have excluded the list of cities from Table 1.

Table 1 presents data on the results of the Fear of COVID-19 Scale and the СOVID-19 Preventive Behavior Index. Therefore, it would be more appropriate to give Table 1 after the explanations of these scales.

Thank you for these suggestions, we moved Table 1 to the Results section, so that readers can see the descriptive statistics for these instruments after they read their descriptions in Methods.

Typos should be corrected.

Thank you for this suggestion. We have proofread the manuscript and had the text proofread by a native English-speaking editor who used British spelling.

Why didn't the authors exclude any patients with any previous psychological or psychiatric illnesses?

Indeed, we did not specifically exclude patients with any prior psychological or psychiatric illnesses for several reasons. Firstly, The Somatic Symptom Scale-8 used in our study fairly accurately assesses the DSM-5 somatic symptom disorder (AUC = 0,71; 95% CI = 0,66-0,77, according to Toussaint et al., 2020). This implies that more than a third of our sample (37% of participants) meet the criteria for somatic symptom disorder. Moreover, a meta-analytic review has shown that at least a third of patients with somatoform disorders have comorbid anxiety and depressive disorders (Henningsen et al., 2003). Given this, somatic symptoms and mental disorders emerge as quite difficult to differentiate, and we believe that doing it would make the sample of individuals with somatic symptoms less representative.

Secondly, our study was carried out in an online setting, where we could not be sure that the participants would objectively assess their psychological state or honestly report a psychiatric diagnosis. And, finally, there is evidence indicating that many disorders are diagnosed in Russia extremely rarely: for instance, only 1-4% of cases of bipolar affective disorder, depression, anxiety disorders are diagnosed by specialists (Martynikhin, 2021): as a result, most Russian participants with mental comorbidities would probably never be aware of the fact.

However, we totally agree with you that excluding patients with a history of psychiatric illnesses could affect our findings and we described this as a limitation of the current study (“The online survey limits our ability to highlight possible physiological causes of reported somatic symptoms, which may be associated with mental and physical disorders”) and a prospect for future research (“Future studies should rely on objective characteristics (medical records, laboratory tests, physician evaluations, etc.)”).

Henningsen P., Zimmermann T., Sattel H. (2003). Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosomatic Medicine, 65, 528–533. https://doi.org/10.1097/01.psy.0000075977.90337.e7

Martynikhin, I. A. (2021). The use of ICD-10 for diagnosing mental disorders in Russia, according to national statistics and a survey of psychiatrists’ experience. Consortium Psychiatricum, 2(2), 35-44. https://consortium-psy.com/jour/article/view/69/pdf

Toussaint A., Hüsing P., Kohlmann S., & Löwe B. (2020). Detecting DSM-5 somatic symptom disorder: criterion validity of the Patient Health Questionnaire-15 (PHQ-15) and the Somatic Symptom Scale-8 (SSS-8) in combination with the Somatic Symptom Disorder – B Criteria Scale (SSD-12). Psychological Medicine 50, 324–333. https://doi.org/10.1017/S003329171900014X

Do we have any information about previous health problems of the participants? There might appear a difference between those who have and those who don't have.

Our questionnaire contained only one question about the respondents' objective health status ("Do you think you were sick with COVID-19?"). We did not ask about chronic illnesses and other possible medical causes of somatic symptoms for the same reasons as we did not ask about psychiatric illnesses. We agree that this is a very serious question and we also noted this in the Limitations section: “”

In somatic symptom scale, authors state that there are 4 levels of symptoms: minimal, low, medium, high, very high. However in latent profiles there are only low, medium and high levels. Can the authors explain why they reduced the number of profile classes? (It's stated that goodness for fit model does not indicate the superiority of any other).

The authors of the Somatic Symptom Scale-8 distinguish five levels of somatic burden: minimal, low, medium, high, and very high (Gierk et al., 2013). In choosing the number of latent profiles, we relied on a combination of information criteria, entropy, and interpretability of the resulting classes. In particular, the 5-profile model had higher AIC and BIC values, suggesting that this number of profiles is excessive. Based on a combination of theoretical and empirical considerations, in line with some existing studies (Burri et al., 2017; Eliasen et al., 2018; Kato et al., 2010), we opted for a 3-profile model that, as we believe, is parsimonious and at the same time sufficiently theoretically clear.

Burri A, Hilpert P, McNair P, Williams FM. Exploring symptoms of somatization in chronic widespread pain: Latent class analysis and the role of personality. J. Pain Res. 2017; 10:1733–1740. https://doi.org/10.2147/JPR.S139700

Eliasen M, Schröder A, Fink P, Kreiner S, Dantoft TM, Poulsen CH, et al. A step towards a new delimitation of functional somatic syndromes: A latent class analysis of symptoms in a population-based cohort study. J. Psychosom. Res. 2018; 108:102–117. https://doi.org/10.1016/j.jpsychores.2018.03.002

Gierk B., Kohlmann S., Kroenke K., Spangenberg L., Zenger M., Brähler E., et al. The somatic symptom scale-8 (SSS-8): A brief measure of somatic symptom burden. JAMA Internal Meicine, 174(3), 399–407. https://doi.org/10.1001/jamainternmed.2013.12179

Kato K, Sullivan PF, Pedersen NL. Latent class analysis of functional somatic symptoms in a population-based sample of twins. J. Psychosom. Res. 2010; 68(5):447–453. https://doi.org/10.1016/j.jpsychores.2010.01.010

Although females are given and discussed as higher somatizers, it is said in associated factors of somatic burden that 'low somatisers were more often females'. This should be corrected.

Thank you so much for helping us see and correct this mistake, which was a typo. While proofreading the text, we found another similar mistake in the description of the latent profiles (‘more frequently reported history of COVID-19 disease’ instead of ‘more rarely reported history of COVID-19 disease’). All errors have been corrected.

Authors should explain their selection criteria for the multinomial regression model.

We tried to explain selection criteria for the multinomial regression model by adding the following sentence to the Introduction: ‘Specifically, we presumed that somatic burden during the COVID-19 pandemic is associated with known pre-pandemic risk factors (female gender, older age, not being in a partnership, lower education background) [18; 19; 20], but is more dependent on health- and pandemic-related risk factors (poorer self-rated health, history of COVID-19 disease, refusing vaccination against SARS-CoV-2 infection, greater fear of COVID-19 pandemic, living in regions with higher excess mortality, and preventive behavior during the COVID-19 pandemic)’. We also cited additional sources to justify the choice of predictors.

May authors also discuss the reasons for differences between different cities or regions? Do any of these regions have any specific characteristics?

We think there could be many reasons for differences between different cities or regions, as we write about in the Discussion: ‘Variation in prevalence between Russia’s regions can be related to a large number of factors such as geographic features, socioeconomic status, rates of morbidity and mortality from SARS-CoV-2 infection, residents’ attitudes toward the COVID-19 pandemic, and trust in local government authorities’. This is a very important and interesting question, which needs to be explored in the following studies, as the procedures and methods of diagnosing the COVID-19 disease, the patient routing protocols in case of positive results, and the algorithms for inpatient and outpatient treatment were the same throughout Russia (in accordance with the orders of the Ministry of Health).

Once again, we thank you for your help and we hope that we have corrected all the inconsistencies and explained all the shortcomings.

With best regards,

authors.

Decision Letter 1

Ahmet Murt

12 Dec 2022

PONE-D-22-18719R1Somatic burden in Russia during the COVID-19 pandemicPLOS ONE

Dear Dr. Zolotareva,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

==============================

Please submit your revised manuscript by Jan 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ahmet Murt

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Dear Authors,

Our reviewers stated that the link for your data was not active. Can you please check and assure that your data is available as you stated in your manuscript.

Thank you for your contribution to our journal.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The suggestions in the previous round were all applied. The authors should not forget to make the data of this study fully available.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Mar 10;18(3):e0282345. doi: 10.1371/journal.pone.0282345.r004

Author response to Decision Letter 1


28 Jan 2023

Dear Reviewers,

Thank you for your help in improving our manuscript!

We had probably included a peer-review link only. We have now replaced it with a link to our dataset in the OSF repository (https://osf.io/9hw52/) that is publicly available without restrictions.

Best regards,

the authors.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Ahmet Murt

14 Feb 2023

Somatic burden in Russia during the COVID-19 pandemic

PONE-D-22-18719R2

Dear Dr. Zolotareva,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ahmet Murt

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for your efforts to answer the reviewers' concerns.

Reviewers' comments:

Acceptance letter

Ahmet Murt

28 Feb 2023

PONE-D-22-18719R2

Somatic burden in Russia during the COVID-19 pandemic

Dear Dr. Zolotareva:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ahmet Murt

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The study data are available at https://osf.io/9hw52/.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES